New York, USA, March 06, 2025 (GLOBE NEWSWIRE) -- TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight T-cell ...

"This next-generation approach, called ALA-CART (adjunctive LAT-activating CAR-T cells), optimizes CAR-T cells to more effectively eliminate cancer cells, including those that have been able to ...

Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and develop ...

Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, today ...

Having driven the older Cupra in Endurance events with Capture Motorsport, the chance to race in TCR UK with the Gen2 Cupra was one I couldn’t pass up,” said Saunders. “I’ve done some testing in the ...

Researchers have developed ALA-CART, a next-generation therapy aimed at improving outcomes for patients with resistant cancers. Scientists have supercharged CAR-T therapy, making it more powerful ...

Our Bureau, Mumbai Thursday, March 13, 2025, 14:15 Hrs [IST] ...

2seventy bio worked with BMS on the development of BCMA-directed CAR-T therapy Abecma (idecabtagene vicleucel), used to treat ...